A Pharmacokinetic and Endoscopic Comparison of an Oral and an Experimental Buccal Piroxicam Formulation

Bruce A. Mueller, Douglas K. Rex, Neysa Figueroa, Paula Greene, D. Craig Brater

Research output: Contribution to journalArticle

4 Scopus citations


We compared the endoscopic effects and pharmacokinetic profiles of an experimental buccal formulation of piroxicam to oral capsules in an attempt to determine whether nonsteroidal antiinflammatory drug-induced gastropathy is due to a local or systemic effect. Ten healthy subjects received 20 mg piroxicam daily in a double-blind, randomized, crossover, placebo-controlled study. Upper endoscopies were performed at the baseline and at the end of each 2-week dosing arm of the study. Pharmacokinetic data obtained included serum and gastric piroxicam concentrations and serum 5'-hydroxypiroxicam metabolite concentrations after the first dose and 2 weeks of dosing. No differences in endoscopy scores or patient symptom scores were noted between the two dosage forms after 2 weeks of dosing. Pharmacokinetic data of piroxicam and the metabolite revealed that the buccal formulation may not have been absorbed exclusively from the buccal mucosa.

Original languageEnglish (US)
Pages (from-to)93-97
Number of pages5
JournalPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Issue number2
StatePublished - Jan 1 1992


ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this